SlideShare a Scribd company logo
Essentials of survival analysis
How to practice evidence based
oncology
European School of Oncology
July 2004
Antwerp, Belgium
Dr. Iztok Hozo
Professor of Mathematics
Indiana University NW
www.iun.edu/~mathiho
Time-to-Event
 Time-to-event data are generated when the measure of interest is
the amount of time to occurrence of an event of interest.
 For Example:
 – Time from randomization to death in clinical trial
 – Time from randomization to recurrence in a cancer clinical trial
 – Time from diagnosis of cancer to death due to the cancer
 – Time from diagnosis of cancer to death due to any causes
 – Time from remission to relapse of leukemia
 – Time from HIV infection to AIDS
 – Time from exposure to cancer incidence in an epidemiological
cohort study
Censoring
 Censoring occurs when we have some information, but we don’t know
the exact time-to-event measure.
 For example, patients typically enter a clinical study at the time
randomization (or the time of diagnosis, or treatment) and are followed
up until the event of interest is observed.
However, censoring may occur for the following reasons:
 a person does not experience the event before the study ends;
 death due to a cause not considered to be the event of interest (traffic
accident, adverse drug reaction,…); and
 loss to follow-up, for example, if the person moves.
We say that the survival time is censored. These are examples of right
censoring, which is the most common form of censoring in medical
studies. For these patients, the complete time-to-event measure is
unknown; we only know that the true time-to-event measure is greater
than the observed measurement.
Example:
X means an event occurred; O means that the subject was censored.
Example 2 (from Kleinbaum: “Survival Analysis”)
Patient Time (t) Censor (d)
1 23 1
2 47 1
3 69 1
4 70 0
5 71 0
6 100 0
7 101 0
8 148 1
9 181 1
10 198 0
11 208 0
12 212 0
13 224 0
Consider data from a retrospective
study of 13 women who had surgery
for breast cancer. The survival times
are:
23, 47, 69, 70+, 71+, 100+, 101+,
148, 181, 198+, 208+, 212+, 224+
(the “+” means that that particular patient was
censored)
Survival Curve - Calculus
 S(t) = cumulative survival function = proportion that survive until time t
f(t) = frequency distribution of age at death
h(t) = hazard function (i.e. death rate at age t) = event rate
 Relationships:
     
 

 
t
duuh
t
eduuftTPtS 0
   
dt
tdS
tf 
   
 
 
 
 
  tS
dt
d
tS
tf
TtPt
ttTtP
t
TtttTtP
th
t
t
lnlim
|
lim
0
0









Distribution Function, Survival Function
and Density Function
)(1)Pr()( tFtTtS 
 Probability Distribution function
 Probability Density function
 Survival function t
tF
tf



)(
)(
)Pr()( tTtF 
Creating a Kaplan-Meier curve
j
jj
n
dn 
 211 |   jjj tTtTPt
     
   
1
11
1
11
0132
21
|...|
|
n
dn
n
dn
n
dn
tTtTPtTtTP
tTtTPtTPtS
j
jj
j
jj
jj
jj













For each non-censored failure time tj (time-to-event time) evaluate:
•nj = number at risk before time tj
•dj = number of deaths from tj-1 to tj
•Fraction
= estimated probability of surviving past tj-1
given that you are at risk at time
The Product Limit Formula:
Kaplan-Meier Product Limit Estimate
Consider data from a retrospective study of 45 women who had surgery for breast cancer. The
survival times are: 23, 47, 69, 70+, 71+, 100+, 101+, 148, 181, 198+, 208+, 212+, 224+
j Interval n j d j S (t)
1 13 0 1.00 1.00
2 13 1 0.92 0.92
3 12 1 0.92 0.85
4 11 1 0.91 0.77
5 6 1 0.83 0.64
6 5 1 0.80 0.51
230  t
4723  t
6947  t
14869  t
181148  t
t181
j
jj
n
dn 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0 20 40 60 80 100 120 140 160 180 200
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
0 50 100 150 200
Survival Curves – more examples
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 100 200 300 400 500 600 700 800 900
Days Since Index Hospitalization
Warf
ASA
No Rx
Age 76 Years and Older (N = 394)
Log-Rank test for two groups
 Suppose we have two groups,
each with a different treatment.
Usually, we represent this kind
of situation in a 2x2 table.
Event No Event
Intervention 45 198
Control 52 203
or
# at Risk # Events
Intervention n1 = 243 m1 = 45
Control n2 = 255 m2 = 52
TOTAL: N = 498 M = 97
Expected number of events:
Intervention 47.33
Control 49.67
Observed- Expected: -2.33
Variance: 19.55
   
 risktotal
eventstotal
groupExpected
__#
__#
# 
 
 12
21



NN
MNMnn
Var
ExpectedObservedEO 
 If the data are given through time, we have a series of
2x2 tables.
 Expected number of events
If the two groups were the same – what would the
expected number of events be?
 Observed minus expected
This is a measure of deviation of one treatment from
their average (the expected)
 Log-rank statistic measures whether the data in the two
groups are statistically “different”.
Log-Rank test for two groups
Comparing Survival Functions
 Question: Did the treatment make a
difference in the survival experience of
the two groups?
 Hypothesis: H0: S1(t)=S2(t) for all t ≥ 0.
 Three often used tests:
1. Log-rank test (aka Mantel-Haenszel Test);
2. Wilcoxon Test;
3. Likelihood ratio test.
Log-rank example (from Kleinbaum: “Survival Analysis”)
Time n1 m1 n2 m2 Expected Obs-Exp Var
1 21 0 21 2 1.00 -1.00 0.488
2 21 0 19 2 1.05 -1.05 0.486
3 21 0 17 1 0.55 -0.55 0.247
4 21 0 16 2 1.14 -1.14 0.477 Log-rank Statistic
5 21 0 14 2 1.20 -1.20 0.466
6 21 3 12 0 1.91 1.09 0.651
7 17 1 12 0 0.59 0.41 0.243
8 16 0 12 4 2.29 -2.29 0.871
10 15 1 8 0 0.65 0.35 0.227
11 13 0 8 2 1.24 -1.24 0.448 Chi-square p-value
12 12 0 6 2 1.33 -1.33 0.418
13 12 1 4 0 0.75 0.25 0.188
15 11 0 4 1 0.73 -0.73 0.196
16 11 1 3 0 0.79 0.21 0.168
17 10 0 3 1 0.77 -0.77 0.178
22 7 1 2 1 1.56 -0.56 0.302
23 6 1 1 1 1.71 -0.71 0.204
Total: 9 21 -10.25 6.257
16.7929
0.00004
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0 10 20 30
Survival data vs. two-by-two table = different
Timen1 m1 q1 S1 n2 m2 q2 S2
0 21 0 100% 21 0 100%
1 21 0 100% 21 2 90%
2 21 0 100% 19 2 81%
3 21 0 100% 17 1 76%
4 21 0 100% 16 2 67%
5 21 0 100% 14 2 57%
6 21 3 1 86% 12 0 57%
7 17 1 1 81% 12 0 57%
8 16 0 81% 12 4 38%
10 15 1 2 75% 8 0 38%
11 13 0 75% 8 2 29%
12 12 0 75% 6 2 19%
13 12 1 69% 4 0 19%
15 11 0 69% 4 1 14%
16 11 1 3 63% 3 0 14%
17 10 0 63% 3 1 10%
22 7 1 54% 2 1 5%
23 6 1 5 45% 1 1 0%
Total: 9 21
Event no-event Total
Rx1 9 12 21
Rx2 21 0 21
Total 30 12 42
Surv. Rx1 =12/21= 57.1%
Surv. Rx2 =0/21= 0.0%
Log-Rank test for several groups
 The null hypothesis is that all the survival curves are
the same.
 Log-rank statistic is given by the sum:
 This statistic has Chi-square distribution with (# of
groups – 1) degrees of freedom.
 
 
 






groupsof
i i
ii
groupsof
i ii
ii
E
EO
EOVar
EO
X
__# 2__# 2
2
Cox Proportional Hazards Regression
 Most interesting survival-analysis research examines the
relationship between survival — typically in the form of the
hazard function — and one or more explanatory variables (or
covariates).
 Most common are linear-like models for the log hazard.
 For example, a parametric regression model based on the
exponential distribution,
 Needed to assess effect of multiple covariates on survival
 Cox-proportional hazards is the most commonly used
multivariate survival method
 Easy to implement in SPSS, Stata, or SAS
 Parametric approaches are an alternative, but they require
stronger assumptions about h(t).
 Assumes multiplicative risk—this is the proportional hazard
assumption
 Conveniently separates baseline hazard function from
covariates
 Baseline hazard function over time
 Covariates are time independent
 Nonparametric
 Can handle both continuous and categorical predictor
variables (think: logistic, linear regression)
 Without knowing baseline hazard ho(t), can still calculate
coefficients for each covariate, and therefore hazard ratio
Multivariate methods:
Cox proportional hazards
Limitations of Cox PH model
 Covariates normally do not vary over time
 True with respect to gender, ethnicity, or congenital
condition
 One can program time-dependent variables
 Baseline hazard function, ho(t), is never specified, but
Cox PH models known hazard functions
 You can estimate ho(t) accurately if you need to estimate
S(t).
Hazard Ratio
 Interesting to interpret
For example, if HR = 0.70, we can deduce the following:
 Relative effect on survival is
or 30% reduction of the risk of death
 Absolute Difference in survival is given as
so, if S = 60%,
which represents a 10% difference.
 Difference in median survival is given as the difference between the
median/HR and the median. For example, if the median is
months, then the difference is given as
or 10.71 months increase in median survival.
30.070.011  HR
 
SSSe HRHRS
ln
10.060.060.0 70.0
AbsDiff
25
71.1025
70.0
25

V
EO
eHR



More Related Content

What's hot

Survival Analysis
Survival AnalysisSurvival Analysis
Survival Analysis
SMAliKazemi
 
Basic survival analysis
Basic survival analysisBasic survival analysis
Basic survival analysis
Mike LaValley
 
Survival analysis
Survival analysis  Survival analysis
Survival analysis
vijaylaxmi hasaraddi
 
Survival analysis 1
Survival analysis 1Survival analysis 1
Survival analysis 1
KyusonLim
 
Cox model
Cox modelCox model
Cox model
Veronica Navia
 
Survival Analysis Using SPSS
Survival Analysis Using SPSSSurvival Analysis Using SPSS
Survival Analysis Using SPSS
Nermin Osman
 
Survival analysis & Kaplan Meire
Survival analysis & Kaplan MeireSurvival analysis & Kaplan Meire
Survival analysis & Kaplan Meire
Dr Athar Khan
 
SURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.pptSURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.ppt
mbang ernest
 
Introduction To Survival Analysis
Introduction To Survival AnalysisIntroduction To Survival Analysis
Introduction To Survival Analysis
federicorotolo
 
Survival analysis
Survival analysisSurvival analysis
Survival analysis
Har Jindal
 
5 essential steps for sample size determination in clinical trials slideshare
5 essential steps for sample size determination in clinical trials   slideshare5 essential steps for sample size determination in clinical trials   slideshare
5 essential steps for sample size determination in clinical trials slideshare
nQuery
 
Multiple Regression and Logistic Regression
Multiple Regression and Logistic RegressionMultiple Regression and Logistic Regression
Multiple Regression and Logistic Regression
Kaushik Rajan
 
Life Tables & Kaplan-Meier Method.pptx
 Life Tables & Kaplan-Meier Method.pptx Life Tables & Kaplan-Meier Method.pptx
Life Tables & Kaplan-Meier Method.pptx
Pravin Kolekar
 
Poisson regression models for count data
Poisson regression models for count dataPoisson regression models for count data
Poisson regression models for count data
University of Southampton
 
Binary OR Binomial logistic regression
Binary OR Binomial logistic regression Binary OR Binomial logistic regression
Binary OR Binomial logistic regression
Dr Athar Khan
 
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik JakartaSurvival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
Setia Pramana
 
Logistic Ordinal Regression
Logistic Ordinal RegressionLogistic Ordinal Regression
Logistic Ordinal Regression
Sri Ambati
 
Logistic regression
Logistic regressionLogistic regression
Logistic regression
Khaled Abd Elaziz
 
Chi square
Chi squareChi square

What's hot (20)

Survival Analysis
Survival AnalysisSurvival Analysis
Survival Analysis
 
Basic survival analysis
Basic survival analysisBasic survival analysis
Basic survival analysis
 
Survival analysis
Survival analysis  Survival analysis
Survival analysis
 
Survival analysis 1
Survival analysis 1Survival analysis 1
Survival analysis 1
 
Cox model
Cox modelCox model
Cox model
 
Survival Analysis Using SPSS
Survival Analysis Using SPSSSurvival Analysis Using SPSS
Survival Analysis Using SPSS
 
Survival analysis & Kaplan Meire
Survival analysis & Kaplan MeireSurvival analysis & Kaplan Meire
Survival analysis & Kaplan Meire
 
SURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.pptSURVIVAL ANALYSIS.ppt
SURVIVAL ANALYSIS.ppt
 
Introduction To Survival Analysis
Introduction To Survival AnalysisIntroduction To Survival Analysis
Introduction To Survival Analysis
 
Survival analysis
Survival analysisSurvival analysis
Survival analysis
 
Part 1 Survival Analysis
Part 1 Survival AnalysisPart 1 Survival Analysis
Part 1 Survival Analysis
 
5 essential steps for sample size determination in clinical trials slideshare
5 essential steps for sample size determination in clinical trials   slideshare5 essential steps for sample size determination in clinical trials   slideshare
5 essential steps for sample size determination in clinical trials slideshare
 
Multiple Regression and Logistic Regression
Multiple Regression and Logistic RegressionMultiple Regression and Logistic Regression
Multiple Regression and Logistic Regression
 
Life Tables & Kaplan-Meier Method.pptx
 Life Tables & Kaplan-Meier Method.pptx Life Tables & Kaplan-Meier Method.pptx
Life Tables & Kaplan-Meier Method.pptx
 
Poisson regression models for count data
Poisson regression models for count dataPoisson regression models for count data
Poisson regression models for count data
 
Binary OR Binomial logistic regression
Binary OR Binomial logistic regression Binary OR Binomial logistic regression
Binary OR Binomial logistic regression
 
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik JakartaSurvival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
Survival Data Analysis for Sekolah Tinggi Ilmu Statistik Jakarta
 
Logistic Ordinal Regression
Logistic Ordinal RegressionLogistic Ordinal Regression
Logistic Ordinal Regression
 
Logistic regression
Logistic regressionLogistic regression
Logistic regression
 
Chi square
Chi squareChi square
Chi square
 

Similar to Survival analysis

lecture1 on survival analysis HRP 262 class
lecture1 on survival analysis HRP 262 classlecture1 on survival analysis HRP 262 class
lecture1 on survival analysis HRP 262 class
TroyTeo1
 
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
Waqas Tariq
 
Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)
Evangelos Kritsotakis
 
Art01
Art01Art01
Biostat_Chapter6_Part3.pdf Bio Statistics
Biostat_Chapter6_Part3.pdf Bio StatisticsBiostat_Chapter6_Part3.pdf Bio Statistics
Biostat_Chapter6_Part3.pdf Bio Statistics
ArwaAbdelHamid1
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
Big Data Analytics for Healthcare
Big Data Analytics for HealthcareBig Data Analytics for Healthcare
Big Data Analytics for Healthcare
Chandan Reddy
 
slides Testing of hypothesis.pptx
slides Testing  of  hypothesis.pptxslides Testing  of  hypothesis.pptx
slides Testing of hypothesis.pptx
ssuser504dda
 
Simulation Study for Extended AUC In Disease Risk Prediction in survival anal...
Simulation Study for Extended AUC In Disease Risk Prediction in survival anal...Simulation Study for Extended AUC In Disease Risk Prediction in survival anal...
Simulation Study for Extended AUC In Disease Risk Prediction in survival anal...Gang Cui
 
TestSurvRec manual
TestSurvRec manualTestSurvRec manual
TestSurvRec manual
Carlos M Martínez M
 
Chapter 11Survival AnalysisLearning Objectives.docx
Chapter 11Survival AnalysisLearning Objectives.docxChapter 11Survival AnalysisLearning Objectives.docx
Chapter 11Survival AnalysisLearning Objectives.docx
keturahhazelhurst
 
Shocktraumamodel Mmvr2005
Shocktraumamodel Mmvr2005Shocktraumamodel Mmvr2005
Shocktraumamodel Mmvr2005martindudziak
 
Linear Modeling Survival Analysis Statistics Assignment Help
Linear Modeling Survival Analysis Statistics Assignment HelpLinear Modeling Survival Analysis Statistics Assignment Help
Linear Modeling Survival Analysis Statistics Assignment Help
Statistics Assignment Experts
 
t-test and one way ANOVA.ppt game.ppt
t-test and one way ANOVA.ppt game.pptt-test and one way ANOVA.ppt game.ppt
t-test and one way ANOVA.ppt game.ppt
MohammedAbdela7
 
Repeated events analyses
Repeated events analysesRepeated events analyses
Repeated events analyses
Mike LaValley
 
Answer the following.   (5 pts ea)A study is conducted to estimate.docx
Answer the following.   (5 pts ea)A study is conducted to estimate.docxAnswer the following.   (5 pts ea)A study is conducted to estimate.docx
Answer the following.   (5 pts ea)A study is conducted to estimate.docx
boyfieldhouse
 
Statistical analysis by iswar
Statistical analysis by iswarStatistical analysis by iswar

Similar to Survival analysis (20)

lecture1 on survival analysis HRP 262 class
lecture1 on survival analysis HRP 262 classlecture1 on survival analysis HRP 262 class
lecture1 on survival analysis HRP 262 class
 
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
Use Proportional Hazards Regression Method To Analyze The Survival of Patient...
 
Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)Common statistical pitfalls & errors in biomedical research (a top-5 list)
Common statistical pitfalls & errors in biomedical research (a top-5 list)
 
Art01
Art01Art01
Art01
 
Biostat_Chapter6_Part3.pdf Bio Statistics
Biostat_Chapter6_Part3.pdf Bio StatisticsBiostat_Chapter6_Part3.pdf Bio Statistics
Biostat_Chapter6_Part3.pdf Bio Statistics
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Big Data Analytics for Healthcare
Big Data Analytics for HealthcareBig Data Analytics for Healthcare
Big Data Analytics for Healthcare
 
slides Testing of hypothesis.pptx
slides Testing  of  hypothesis.pptxslides Testing  of  hypothesis.pptx
slides Testing of hypothesis.pptx
 
Simulation Study for Extended AUC In Disease Risk Prediction in survival anal...
Simulation Study for Extended AUC In Disease Risk Prediction in survival anal...Simulation Study for Extended AUC In Disease Risk Prediction in survival anal...
Simulation Study for Extended AUC In Disease Risk Prediction in survival anal...
 
TestSurvRec manual
TestSurvRec manualTestSurvRec manual
TestSurvRec manual
 
Chapter 11Survival AnalysisLearning Objectives.docx
Chapter 11Survival AnalysisLearning Objectives.docxChapter 11Survival AnalysisLearning Objectives.docx
Chapter 11Survival AnalysisLearning Objectives.docx
 
Shocktraumamodel Mmvr2005
Shocktraumamodel Mmvr2005Shocktraumamodel Mmvr2005
Shocktraumamodel Mmvr2005
 
Statistics78 (2)
Statistics78 (2)Statistics78 (2)
Statistics78 (2)
 
Linear Modeling Survival Analysis Statistics Assignment Help
Linear Modeling Survival Analysis Statistics Assignment HelpLinear Modeling Survival Analysis Statistics Assignment Help
Linear Modeling Survival Analysis Statistics Assignment Help
 
t-test and one way ANOVA.ppt game.ppt
t-test and one way ANOVA.ppt game.pptt-test and one way ANOVA.ppt game.ppt
t-test and one way ANOVA.ppt game.ppt
 
Repeated events analyses
Repeated events analysesRepeated events analyses
Repeated events analyses
 
Answer the following.   (5 pts ea)A study is conducted to estimate.docx
Answer the following.   (5 pts ea)A study is conducted to estimate.docxAnswer the following.   (5 pts ea)A study is conducted to estimate.docx
Answer the following.   (5 pts ea)A study is conducted to estimate.docx
 
Statistical analysis by iswar
Statistical analysis by iswarStatistical analysis by iswar
Statistical analysis by iswar
 
Quantitative Synthesis I
Quantitative Synthesis IQuantitative Synthesis I
Quantitative Synthesis I
 

Recently uploaded

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
Catherine Liao
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 

Recently uploaded (20)

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...The hemodynamic and autonomic determinants of elevated blood pressure in obes...
The hemodynamic and autonomic determinants of elevated blood pressure in obes...
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 

Survival analysis

  • 1. Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor of Mathematics Indiana University NW www.iun.edu/~mathiho
  • 2. Time-to-Event  Time-to-event data are generated when the measure of interest is the amount of time to occurrence of an event of interest.  For Example:  – Time from randomization to death in clinical trial  – Time from randomization to recurrence in a cancer clinical trial  – Time from diagnosis of cancer to death due to the cancer  – Time from diagnosis of cancer to death due to any causes  – Time from remission to relapse of leukemia  – Time from HIV infection to AIDS  – Time from exposure to cancer incidence in an epidemiological cohort study
  • 3. Censoring  Censoring occurs when we have some information, but we don’t know the exact time-to-event measure.  For example, patients typically enter a clinical study at the time randomization (or the time of diagnosis, or treatment) and are followed up until the event of interest is observed. However, censoring may occur for the following reasons:  a person does not experience the event before the study ends;  death due to a cause not considered to be the event of interest (traffic accident, adverse drug reaction,…); and  loss to follow-up, for example, if the person moves. We say that the survival time is censored. These are examples of right censoring, which is the most common form of censoring in medical studies. For these patients, the complete time-to-event measure is unknown; we only know that the true time-to-event measure is greater than the observed measurement.
  • 4. Example: X means an event occurred; O means that the subject was censored.
  • 5. Example 2 (from Kleinbaum: “Survival Analysis”) Patient Time (t) Censor (d) 1 23 1 2 47 1 3 69 1 4 70 0 5 71 0 6 100 0 7 101 0 8 148 1 9 181 1 10 198 0 11 208 0 12 212 0 13 224 0 Consider data from a retrospective study of 13 women who had surgery for breast cancer. The survival times are: 23, 47, 69, 70+, 71+, 100+, 101+, 148, 181, 198+, 208+, 212+, 224+ (the “+” means that that particular patient was censored)
  • 6. Survival Curve - Calculus  S(t) = cumulative survival function = proportion that survive until time t f(t) = frequency distribution of age at death h(t) = hazard function (i.e. death rate at age t) = event rate  Relationships:            t duuh t eduuftTPtS 0     dt tdS tf                tS dt d tS tf TtPt ttTtP t TtttTtP th t t lnlim | lim 0 0         
  • 7. Distribution Function, Survival Function and Density Function )(1)Pr()( tFtTtS   Probability Distribution function  Probability Density function  Survival function t tF tf    )( )( )Pr()( tTtF 
  • 8. Creating a Kaplan-Meier curve j jj n dn   211 |   jjj tTtTPt           1 11 1 11 0132 21 |...| | n dn n dn n dn tTtTPtTtTP tTtTPtTPtS j jj j jj jj jj              For each non-censored failure time tj (time-to-event time) evaluate: •nj = number at risk before time tj •dj = number of deaths from tj-1 to tj •Fraction = estimated probability of surviving past tj-1 given that you are at risk at time The Product Limit Formula:
  • 9. Kaplan-Meier Product Limit Estimate Consider data from a retrospective study of 45 women who had surgery for breast cancer. The survival times are: 23, 47, 69, 70+, 71+, 100+, 101+, 148, 181, 198+, 208+, 212+, 224+ j Interval n j d j S (t) 1 13 0 1.00 1.00 2 13 1 0.92 0.92 3 12 1 0.92 0.85 4 11 1 0.91 0.77 5 6 1 0.83 0.64 6 5 1 0.80 0.51 230  t 4723  t 6947  t 14869  t 181148  t t181 j jj n dn  0.00 0.20 0.40 0.60 0.80 1.00 1.20 0 20 40 60 80 100 120 140 160 180 200
  • 11. Survival Curves – more examples 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 0 100 200 300 400 500 600 700 800 900 Days Since Index Hospitalization Warf ASA No Rx Age 76 Years and Older (N = 394)
  • 12. Log-Rank test for two groups  Suppose we have two groups, each with a different treatment. Usually, we represent this kind of situation in a 2x2 table. Event No Event Intervention 45 198 Control 52 203 or # at Risk # Events Intervention n1 = 243 m1 = 45 Control n2 = 255 m2 = 52 TOTAL: N = 498 M = 97 Expected number of events: Intervention 47.33 Control 49.67 Observed- Expected: -2.33 Variance: 19.55      risktotal eventstotal groupExpected __# __# #     12 21    NN MNMnn Var ExpectedObservedEO 
  • 13.  If the data are given through time, we have a series of 2x2 tables.  Expected number of events If the two groups were the same – what would the expected number of events be?  Observed minus expected This is a measure of deviation of one treatment from their average (the expected)  Log-rank statistic measures whether the data in the two groups are statistically “different”. Log-Rank test for two groups
  • 14. Comparing Survival Functions  Question: Did the treatment make a difference in the survival experience of the two groups?  Hypothesis: H0: S1(t)=S2(t) for all t ≥ 0.  Three often used tests: 1. Log-rank test (aka Mantel-Haenszel Test); 2. Wilcoxon Test; 3. Likelihood ratio test.
  • 15. Log-rank example (from Kleinbaum: “Survival Analysis”) Time n1 m1 n2 m2 Expected Obs-Exp Var 1 21 0 21 2 1.00 -1.00 0.488 2 21 0 19 2 1.05 -1.05 0.486 3 21 0 17 1 0.55 -0.55 0.247 4 21 0 16 2 1.14 -1.14 0.477 Log-rank Statistic 5 21 0 14 2 1.20 -1.20 0.466 6 21 3 12 0 1.91 1.09 0.651 7 17 1 12 0 0.59 0.41 0.243 8 16 0 12 4 2.29 -2.29 0.871 10 15 1 8 0 0.65 0.35 0.227 11 13 0 8 2 1.24 -1.24 0.448 Chi-square p-value 12 12 0 6 2 1.33 -1.33 0.418 13 12 1 4 0 0.75 0.25 0.188 15 11 0 4 1 0.73 -0.73 0.196 16 11 1 3 0 0.79 0.21 0.168 17 10 0 3 1 0.77 -0.77 0.178 22 7 1 2 1 1.56 -0.56 0.302 23 6 1 1 1 1.71 -0.71 0.204 Total: 9 21 -10.25 6.257 16.7929 0.00004
  • 17. Survival data vs. two-by-two table = different Timen1 m1 q1 S1 n2 m2 q2 S2 0 21 0 100% 21 0 100% 1 21 0 100% 21 2 90% 2 21 0 100% 19 2 81% 3 21 0 100% 17 1 76% 4 21 0 100% 16 2 67% 5 21 0 100% 14 2 57% 6 21 3 1 86% 12 0 57% 7 17 1 1 81% 12 0 57% 8 16 0 81% 12 4 38% 10 15 1 2 75% 8 0 38% 11 13 0 75% 8 2 29% 12 12 0 75% 6 2 19% 13 12 1 69% 4 0 19% 15 11 0 69% 4 1 14% 16 11 1 3 63% 3 0 14% 17 10 0 63% 3 1 10% 22 7 1 54% 2 1 5% 23 6 1 5 45% 1 1 0% Total: 9 21 Event no-event Total Rx1 9 12 21 Rx2 21 0 21 Total 30 12 42 Surv. Rx1 =12/21= 57.1% Surv. Rx2 =0/21= 0.0%
  • 18. Log-Rank test for several groups  The null hypothesis is that all the survival curves are the same.  Log-rank statistic is given by the sum:  This statistic has Chi-square distribution with (# of groups – 1) degrees of freedom.             groupsof i i ii groupsof i ii ii E EO EOVar EO X __# 2__# 2 2
  • 19. Cox Proportional Hazards Regression  Most interesting survival-analysis research examines the relationship between survival — typically in the form of the hazard function — and one or more explanatory variables (or covariates).  Most common are linear-like models for the log hazard.  For example, a parametric regression model based on the exponential distribution,  Needed to assess effect of multiple covariates on survival  Cox-proportional hazards is the most commonly used multivariate survival method  Easy to implement in SPSS, Stata, or SAS  Parametric approaches are an alternative, but they require stronger assumptions about h(t).
  • 20.  Assumes multiplicative risk—this is the proportional hazard assumption  Conveniently separates baseline hazard function from covariates  Baseline hazard function over time  Covariates are time independent  Nonparametric  Can handle both continuous and categorical predictor variables (think: logistic, linear regression)  Without knowing baseline hazard ho(t), can still calculate coefficients for each covariate, and therefore hazard ratio Multivariate methods: Cox proportional hazards
  • 21. Limitations of Cox PH model  Covariates normally do not vary over time  True with respect to gender, ethnicity, or congenital condition  One can program time-dependent variables  Baseline hazard function, ho(t), is never specified, but Cox PH models known hazard functions  You can estimate ho(t) accurately if you need to estimate S(t).
  • 22. Hazard Ratio  Interesting to interpret For example, if HR = 0.70, we can deduce the following:  Relative effect on survival is or 30% reduction of the risk of death  Absolute Difference in survival is given as so, if S = 60%, which represents a 10% difference.  Difference in median survival is given as the difference between the median/HR and the median. For example, if the median is months, then the difference is given as or 10.71 months increase in median survival. 30.070.011  HR   SSSe HRHRS ln 10.060.060.0 70.0 AbsDiff 25 71.1025 70.0 25  V EO eHR  